 | • レポートコード：MRC2211A040 • 出版社/出版日：Persistence Market Research / 2022年9月 • レポート形態：英文、PDF、406ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査レポートは、腫瘍用医薬品の世界市場について調査し、エグゼクティブサマリー、市場概要、主要市場動向、主要適格基準、市場背景、新型コロナウイルス感染症の危機分析、需要分析・予測、薬効分類別（化学治療、標的治療、免疫治療、ホルモン治療）分析、疾患別（乳がん、肺がん、前立腺がん、大腸がん、腎臓がん）分析、投与経路別（経口、注射剤）分析、流通チャネル別（病院薬局、小売薬局、その他）分析、地域別（北米、中南米、ヨーロッパ、南アジア太平洋、東アジア、中東/アフリカ）分析、仮定、調査手法などを整理しております。本書では、GlaxoSmithKline plc.、Astrazeneca、Merck KGaA、Johnson＆Johnson、Pfizer, Inc.、Bayer AG、Sanofi S.A.、Boehringer Ingelheim、Bausch Health Companies Inc.、Galderma SA、Novartis AG（Alcon）、Arbor Pharmaceuticalsなどの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要適格基準 ・市場背景 ・新型コロナウイルス感染症の危機分析 ・需要分析・予測 ・世界の腫瘍用医薬品市場規模：薬効分類別 - 腫瘍化学治療の市場規模 - 腫瘍標的治療の市場規模 - 腫瘍免疫治療の市場規模 - 腫瘍ホルモン治療の市場規模 ・世界の腫瘍用医薬品市場規模：疾患別 - 乳がんにおける市場規模 - 肺がんにおける市場規模 - 前立腺がんにおける市場規模 - 大腸がんにおける市場規模 - 腎臓がんにおける市場規模 ・世界の腫瘍用医薬品市場規模：投与経路別 - 経口剤の市場規模 - 注射剤の市場規模 ・世界の腫瘍用医薬品市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他流通チャネルの市場規模 ・世界の腫瘍用医薬品市場規模：地域別 - 北米の腫瘍用医薬品市場規模 - 中南米の腫瘍用医薬品市場規模 - ヨーロッパの腫瘍用医薬品市場規模 - 南アジア太平洋の腫瘍用医薬品市場規模 - 東アジアの腫瘍用医薬品市場規模 - 中東/アフリカの腫瘍用医薬品市場規模 ・仮定 ・調査手法 |
Oncology Drugs Market: Scope of Report
The latest publication by Persistence Market Research on the global oncology drugs market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.
Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research’s study. This research study can support readers to know the demand for the global oncology drugs market and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the global oncology drugs market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the global oncology drugs market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.
Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the global oncology drugs market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research’s study on the global oncology drugs market offers information divided into five important segments – drug class, indication, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Class
Chemotherapy
Alkylating Agents
Antimetabolites
Anti-tumour Antibiotics
Topoisomerase Inhibitors
Mitotic Inhibitors
Others
Targeted Therapy
Monoclonal Antibodies
Small Molecule Inhibitors
Immunotherapy
Immune Checkpoint Inhibitors
Cell Therapy and Gene Therapy
Oncolytic Virus Therapy
Cancer Vaccines
Immune System Modulators
Others
Hormonal Therapy
Indication
Breast Cancer
Lung Cancer
Prostate Cancer
Multiple Myeloma
Colorectal Cancer
Non-Hodgkin’s Lymphoma
Kidney Cancer
Chronic lymphocytic Leukemia
Melanoma
Others
Route of Administration
Oral
Injectable
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Key Questions Answered in Report
Which regions will continue to remain the most profitable markets for oncology drugs over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the oncology drugs market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology drugs market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the oncology drugs market more accurate and reliable.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Inclusion
4.1. Key Promotional Strategies, By Manufacturers
4.2. Disease Epidemiology
4.3. Pipeline Assessment
4.4. Regulatory Landscape
4.5. Reimbursement Outlook
4.6. Product Adoption / Usage Analysis
4.7. PESTLE Analysis
4.8. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Industry Market Outlook
5.1.3. Pharmaceutical Industry Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Rise In Incidence of Cancer
5.2.2. Strong Product Pipeline
5.2.3. Strategic Developments By Key Players
5.2.4. Adoption Of Cell And Gene Therapies
5.2.5. Growing Geriatric Population
5.2.6. Regulatory Framework
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
6.1. Impact of COVID-19 – 2021 Market Scenario
6.2. COVID19 and Impact Analysis
7. Global Oncology Drugs Market Demand (in Value US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2012-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2020-2030, By Drug class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug class, 2012-2021
8.3. Current and Future Market Size (US$ Mn) Analysis By Drug class, 2022-2032
8.3.1. Chemotherapy
8.3.1.1. Alkylating agents.
8.3.1.2. Antimetabolites.
8.3.1.3. Anti-tumor antibiotics.
8.3.1.4. Topoisomerase inhibitors.
8.3.1.5. Mitotic inhibitors
8.3.1.6. Others
8.3.2. Targeted Therapy
8.3.2.1. Monoclonal antibodies
8.3.2.2. Small molecule inhibitors
8.3.3. Immunotherapy
8.3.3.1. Immune Checkpoint Inhibitors.
8.3.3.2. Cell Therapy and Gene Therapy
8.3.3.3. Oncolytic Virus Therapy.
8.3.3.4. Cancer Vaccines.
8.3.3.5. Immune System Modulators.
8.3.3.6. Others
8.3.4. Hormonal Therapy
8.4. Market Attractiveness Analysis By Drug class
9. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2020-2030, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2012-2021
9.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Indication, 2022-2032
9.3.1. Breast Cancer
9.3.2. Lung Cancer
9.3.3. Prostate Cancer
9.3.4. Multiple myeloma
9.3.5. Colorectal Cancer
9.3.6. Non-Hodgkin’s lymphoma
9.3.7. Kidney Cancer
9.3.8. Chronic lymphocytic leukemia
9.3.9. Melanoma
9.3.10. Others
9.4. Market Attractiveness Analysis by Indication
10. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2012-2021
10.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Route of Administration, 2022-2032
10.3.1. Oral
10.3.2. Injectable
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2012-2021
11.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Distribution Channel, 2022-2032
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Others
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis by Region, 2012-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. South Asia
12.3.5. East Asia
12.3.6. Oceania
12.3.7. Middle East & Africa(MEA)
12.4. Market Attractiveness Analysis by Region
13. North America Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) by Market Taxonomy, 2012-2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022 – 2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Drug class
13.3.3. By Indication
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug class
13.4.3. By Indication
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Oncology Drugs Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Drug class
13.8.1.2.2. By Indication
13.8.1.2.3. By Route of Administration
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Oncology Drugs Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Drug class
13.8.2.2.2. By Indication
13.8.2.2.3. By Route of Administration
13.8.2.2.4. By Distribution Channel
14. Latin America Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2012-2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022 – 2032
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Drug class
14.3.3. By Indication
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug class
14.4.3. By Indication
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Oncology Drugs Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Drug class
14.8.1.2.2. By Indication
14.8.1.2.3. By Route of Administration
14.8.1.2.4. By Distribution Channel
14.8.2. Mexico Oncology Drugs Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Drug class
14.8.2.2.2. By Indication
14.8.2.2.3. By Route of Administration
14.8.2.2.4. By Distribution Channel
14.8.3. Argentina Oncology Drugs Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Drug class
14.8.3.2.2. By Indication
14.8.3.2.3. By Route of Administration
14.8.3.2.4. By Distribution Channel
15. Europe Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 – 2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Drug class
15.3.3. By Indication
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug class
15.4.3. By Indication
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Oncology Drugs Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Drug class
15.8.1.2.2. By Indication
15.8.1.2.3. By Route of Administration
15.8.1.2.4. By Distribution Channel
15.8.2. Italy Oncology Drugs Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Drug class
15.8.2.2.2. By Indication
15.8.2.2.3. By Route of Administration
15.8.2.2.4. By Distribution Channel
15.8.3. France Oncology Drugs Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Drug class
15.8.3.2.2. By Indication
15.8.3.2.3. By Route of Administration
15.8.3.2.4. By Distribution Channel
15.8.4. U.K. Oncology Drugs Market
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Drug class
15.8.4.2.2. By Indication
15.8.4.2.3. By Route of Administration
15.8.4.2.4. By Distribution Channel
15.8.5. Spain Oncology Drugs Market
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Drug class
15.8.5.2.2. By Indication
15.8.5.2.3. By Route of Administration
15.8.5.2.4. By Distribution Channel
15.8.6. BENELUX Oncology Drugs Market
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Drug class
15.8.6.2.2. By Indication
15.8.6.2.3. By Route of Administration
15.8.6.2.4. By Distribution Channel
15.8.7. Russia Oncology Drugs Market
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Drug class
15.8.7.2.2. By Indication
15.8.7.2.3. By Route of Administration
15.8.7.2.4. By Distribution Channel
16. South Asia Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 – 2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Drug class
16.3.3. By Indication
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug class
16.4.3. By Indication
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Oncology Drugs Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug class
16.8.1.2.2. By Indication
16.8.1.2.3. By Route of Administration
16.8.1.2.4. By Distribution Channel
16.8.2. Thailand Oncology Drugs Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug class
16.8.2.2.2. By Indication
16.8.2.2.3. By Route of Administration
16.8.2.2.4. By Distribution Channel
16.8.3. Indonesia Oncology Drugs Market
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug class
16.8.3.2.2. By Indication
16.8.3.2.3. By Route of Administration
16.8.3.2.4. By Distribution Channel
16.8.4. Malaysia Oncology Drugs Market
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Drug class
16.8.4.2.2. By Indication
16.8.4.2.3. By Route of Administration
16.8.4.2.4. By Distribution Channel
17. East Asia Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 – 2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Drug class
17.3.3. By Indication
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug class
17.4.3. By Indication
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints – Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Oncology Drugs Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug class
17.8.1.2.2. By Indication
17.8.1.2.3. By Route of Administration
17.8.1.2.4. By Distribution Channel
17.8.2. Japan Oncology Drugs Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug class
17.8.2.2.2. By Indication
17.8.2.2.3. By Route of Administration
17.8.2.2.4. By Distribution Channel
17.8.3. South Korea Oncology Drugs Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug class
17.8.3.2.2. By Indication
17.8.3.2.3. By Route of Administration
17.8.3.2.4. By Distribution Channel
18. Oceania Oncology Drugs Market Analysis 2012-2021 and Forecast 2022-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 – 2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. B By Drug class
18.3.3. By Indication
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug class
18.4.3. By Indication
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Country Level Analysis & Forecast
18.5.1. Australia Oncology Drugs Market
18.5.1.1. Introduction
18.5.1.2. Market Analysis and Forecast by Market Taxonomy
18.5.1.2.1. By Drug class
18.5.1.2.2. By Indication
18.5.1.2.3. By Route of Administration
18.5.1.2.4. By Distribution Channel
18.5.2. New Zealand Oncology Drugs Market
18.5.2.1. Introduction
18.5.2.2. Market Analysis and Forecast by Market Taxonomy
18.5.2.2.1. By Drug class
18.5.2.2.2. By Indication
18.5.2.2.3. By Route of Administration
18.5.2.2.4. By Distribution Channel
19. MEA Oncology Drugs Market Analysis 2012-2021and Forecast 2022-2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012-2021
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022 – 2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of MEA
19.3.2. By Drug class
19.3.3. By Indication
19.3.4. By Route of Administration
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug class
19.4.3. By Indication
19.4.4. By Route of Administration
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants – Intensity Mapping
19.7. Drivers and Restraints – Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Oncology Drugs Market
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug class
19.8.1.2.2. By Indication
19.8.1.2.3. By Route of Administration
19.8.1.2.4. By Distribution Channel
19.8.2. Turkey Oncology Drugs Market
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug class
19.8.2.2.2. By Indication
19.8.2.2.3. By Route of Administration
19.8.2.2.4. By Distribution Channel
19.8.3. South Africa Oncology Drugs Market
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Drug class
19.8.3.2.2. By Indication
19.8.3.2.3. By Route of Administration
19.8.3.2.4. By Distribution Channel
19.8.4. North Africa Oncology Drugs Market
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Drug class
19.8.4.2.2. By Indication
19.8.4.2.3. By Route of Administration
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive (Tentative List)
21.3.1. GlaxoSmithKline plc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. SWOT Analysis
21.3.1.4. Strategy Overview
21.3.1.4.1. Marketing Strategies
21.3.1.4.2. Product Strategies
21.3.1.4.3. Channel Strategies
21.3.2. Astrazeneca
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. SWOT Analysis
21.3.2.4. Strategy Overview
21.3.2.4.1. Marketing Strategies
21.3.2.4.2. Product Strategies
21.3.2.4.3. Channel Strategies
21.3.3. Merck KGaA
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. SWOT Analysis
21.3.3.4. Strategy Overview
21.3.3.4.1. Marketing Strategies
21.3.3.4.2. Product Strategies
21.3.3.4.3. Channel Strategies
21.3.4. Johnson & Johnson
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. SWOT Analysis
21.3.4.4. Strategy Overview
21.3.4.4.1. Marketing Strategies
21.3.4.4.2. Product Strategies
21.3.4.4.3. Channel Strategies
21.3.5. Pfizer, Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. SWOT Analysis
21.3.5.4. Strategy Overview
21.3.5.4.1. Marketing Strategies
21.3.5.4.2. Product Strategies
21.3.5.4.3. Channel Strategies
21.3.6. Bayer AG
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. SWOT Analysis
21.3.6.4. Strategy Overview
21.3.6.4.1. Marketing Strategies
21.3.6.4.2. Product Strategies
21.3.6.4.3. Channel Strategies
21.3.7. Sanofi S.A.
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. SWOT Analysis
21.3.7.4. Strategy Overview
21.3.7.4.1. Marketing Strategies
21.3.7.4.2. Product Strategies
21.3.7.4.3. Channel Strategies
21.3.8. Boehringer Ingelheim
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. SWOT Analysis
21.3.8.4. Strategy Overview
21.3.8.4.1. Marketing Strategies
21.3.8.4.2. Product Strategies
21.3.8.4.3. Channel Strategies
21.3.9. Bausch Health Companies Inc.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. SWOT Analysis
21.3.9.4. Strategy Overview
21.3.9.4.1. Marketing Strategies
21.3.9.4.2. Product Strategies
21.3.9.4.3. Channel Strategies
21.3.10. Galderma SA
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. SWOT Analysis
21.3.10.4. Strategy Overview
21.3.10.4.1. Marketing Strategies
21.3.10.4.2. Product Strategies
21.3.10.4.3. Channel Strategies
21.3.11. Novartis AG (Alcon)
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. SWOT Analysis
21.3.11.4. Strategy Overview
21.3.11.4.1. Marketing Strategies
21.3.11.4.2. Product Strategies
21.3.11.4.3. Channel Strategies
21.3.12. Arbor Pharmaceuticals
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. SWOT Analysis
21.3.12.4. Strategy Overview
21.3.12.4.1. Marketing Strategies
21.3.12.4.2. Product Strategies
21.3.12.4.3. Channel Strategies
21.3.13. Perrigo Company Plc.
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. SWOT Analysis
21.3.13.4. Strategy Overview
21.3.13.4.1. Marketing Strategies
21.3.13.4.2. Product Strategies
21.3.13.4.3. Channel Strategies
21.3.14. Allergan
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. SWOT Analysis
21.3.14.4. Strategy Overview
21.3.14.4.1. Marketing Strategies
21.3.14.4.2. Product Strategies
21.3.14.4.3. Channel Strategies
21.3.15. Lupin
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. SWOT Analysis
21.3.15.4. Strategy Overview
21.3.15.4.1. Marketing Strategies
21.3.15.4.2. Product Strategies
21.3.15.4.3. Channel Strategies
21.3.16. Teva pharmaceuticals
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. SWOT Analysis
21.3.16.4. Strategy Overview
21.3.16.4.1. Marketing Strategies
21.3.16.4.2. Product Strategies
21.3.16.4.3. Channel Strategies
21.3.17. Ultragenyx Pharmaceutical Inc
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. SWOT Analysis
21.3.17.4. Strategy Overview
21.3.17.4.1. Marketing Strategies
21.3.17.4.2. Product Strategies
21.3.17.4.3. Channel Strategies
21.3.18. Zydus Cadila Healthcare Ltd.
21.3.18.1. Overview
21.3.18.2. Product Portfolio
21.3.18.3. SWOT Analysis
21.3.18.4. Strategy Overview
21.3.18.4.1. Marketing Strategies
21.3.18.4.2. Product Strategies
21.3.18.4.3. Channel Strategies
21.3.19. Glenmark Pharmaceuticals
21.3.19.1. Overview
21.3.19.2. Product Portfolio
21.3.19.3. SWOT Analysis
21.3.19.4. Strategy Overview
21.3.19.4.1. Marketing Strategies
21.3.19.4.2. Product Strategies
21.3.19.4.3. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
Table 01 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug ClassTable 01 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 02 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 02 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 03 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 03 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 04 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 04 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 05 A: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Region
Table 05 B: Global Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Region
Table 06 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 06 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 07 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 07 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 07 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 07 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 08 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 08 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 09 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 09 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 10 A: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 10 B: North America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 11 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 11 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 12 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 12 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 12 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 12 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 13 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 13 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 14 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 14 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 15 A: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 15 B: Latin America Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 16 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 16 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 17 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 17 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 17 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 17 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 18 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 18 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 19 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 19 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 20 A: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 20 B: Europe Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 21 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 21 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 22 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 22 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 22 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 22 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 23 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 23 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 24 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 24 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 25 A: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 25 B: South Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 26 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 26 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 27 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 27 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 27 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 27 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 28 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 28 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 29 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 29 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 30 A: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 30 B: East Asia Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 31 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 31 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 32 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 32 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 32 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 32 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 33 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 33 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 34 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 34 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 35 A: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 35 B: Oceania Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 36 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 36 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Country
Table 37 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 37 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 37 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 37 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Drug Class
Table 38 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 38 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Indication
Table 39 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 39 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration
Table 40 A: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel
Table 40 B: MEA Oncology Drugs Market Size (US$ Bn) Analysis 2012-2021 and Forecast 2022-2032, By Distribution Channel